Hudock Inc. Raises Position in Novo Nordisk A/S (NYSE:NVO)

Hudock Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 106.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 5,308 shares of the company’s stock after acquiring an additional 2,743 shares during the quarter. Hudock Inc.’s holdings in Novo Nordisk A/S were worth $457,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of NVO. Creative Planning grew its stake in Novo Nordisk A/S by 4.7% in the 3rd quarter. Creative Planning now owns 294,799 shares of the company’s stock valued at $35,102,000 after buying an additional 13,203 shares in the last quarter. Acorn Creek Capital LLC lifted its stake in Novo Nordisk A/S by 7.4% in the third quarter. Acorn Creek Capital LLC now owns 2,299 shares of the company’s stock worth $274,000 after purchasing an additional 159 shares during the last quarter. Asset Dedication LLC lifted its stake in Novo Nordisk A/S by 23.0% in the third quarter. Asset Dedication LLC now owns 2,354 shares of the company’s stock worth $280,000 after purchasing an additional 440 shares during the last quarter. Opal Wealth Advisors LLC lifted its stake in Novo Nordisk A/S by 15.2% in the third quarter. Opal Wealth Advisors LLC now owns 3,171 shares of the company’s stock worth $378,000 after purchasing an additional 418 shares during the last quarter. Finally, Safeguard Financial LLC bought a new stake in Novo Nordisk A/S in the third quarter worth $330,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $81.78 on Thursday. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.75. The company’s 50-day moving average is $90.45 and its 200 day moving average is $110.60. The stock has a market capitalization of $366.99 billion, a P/E ratio of 24.86, a P/E/G ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.86 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.